* ALX Oncology Holdings Inc is expected to show no change in quarterly revenue when it reports results for the period ending December 31 2024
*
* LSEG's mean analyst estimate for ALX Oncology Holdings Inc is for a loss of 72 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.
* Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $6.00, above its last closing price of $1.51.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.78 -0.78 -0.58 Beat 25.6
Jun. 30 2024 -0.77 -0.77 -0.76 Beat 1.7
Jan. 1 0001 -0.85 -0.84 -0.71 Beat 15.1
Dec. 31 2023 -0.81 -0.84 -0.93 Missed -10.5
Sep. -0.82 -0.87 -1.24 Missed -42.5
30 2023
Jun. 30 2023 -0.88 -0.88 -0.84 Beat 4.5
Mar. 31 2023 -0.82 -0.80 -0.74 Beat 7.7
Dec. 31 2022 -0.81 -0.89 -0.75 Beat 15.4
This summary was machine generated November 8 at 15:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。